Sorfequiline

Sorfequiline
Clinical data
Other namesTBAJ-876
Identifiers
  • (1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-2-(2,6-dimethoxy-4-pyridinyl)-4-(dimethylamino)-1-(2,3,6-trimethoxy-4-pyridinyl)butan-2-ol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
PDB ligand
Chemical and physical data
FormulaC31H37BrN4O7
Molar mass657.562 g·mol−1
3D model (JSmol)
  • CN(C)CC[C@@](C1=CC(=NC(=C1)OC)OC)([C@H](C2=CC(=NC(=C2OC)OC)OC)C3=C(N=C4C=CC(=CC4=C3)Br)OC)O
  • InChI=InChI=1S/C31H37BrN4O7/c1-36(2)12-11-31(37,19-15-24(38-3)34-25(16-19)39-4)27(21-17-26(40-5)35-30(43-8)28(21)41-6)22-14-18-13-20(32)9-10-23(18)33-29(22)42-7/h9-10,13-17,27,37H,11-12H2,1-8H3/t27-,31-/m1/s1
  • Key:HHDDKDPLFXIPBX-DLFZDVPBSA-N

Sorfequiline is an investigational new drug that is being evaluated by Global Alliance for TB Drug Development for the treatment of tuberculosis.[1] It is an adenosine triphosphatase inhibitor.[1][2][3][4]

Sorfequiline is a next generation diarylquinoline mycobacterial ATP synthase inhibitor. Compared to bedaquiline, it is claimed to have greater potency and reduced cardiac QT prolongation.[5]

Clinical trials

It is currently in phase 2 clinical trials.[6][7]

References

  1. 1 2 "Sorfequiline". AdisInsight. Springer Nature Switzerland AG. Retrieved 5 July 2026.
  2. ↑ Darpo B, Nedelman J, Bruning-Barry R, Hickman D, Kleiman R, Lombardi A, et al. (March 2026). "Cardiodynamic evaluation of sorfequiline (TBAJ-876): results from a first-in-human study". Antimicrobial Agents and Chemotherapy. 70 (3) e01273-25: e0127325. doi:10.1128/aac.01273-25. PMC 12959150. PMID 41616265.
  3. ↑ Olugbosi M, Beumont M, Lombard L, Nedelman J, Timm J, Black T, et al. (January 2026). "Protocol for a phase 2, partially blinded, randomized trial assessing the safety and efficacy of sorfequiline or bedaquiline in combination with pretomanid and linezolid in adult participants with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis (NC-009)". Trials. 27 (1) 102. doi:10.1186/s13063-025-09413-5. PMC 12869905. PMID 41495827.
  4. ↑ Holt E (December 2025). "Promising early data for sorfequiline". The Lancet. Infectious Diseases. 26 (2): S1473–3099(25)00780–7. doi:10.1016/S1473-3099(25)00780-7. PMID 41429138.
  5. ↑ Enesco A (25 November 2025). "Sorfequiline Shows Promise in Shortened Tuberculosis Therapy". European Medical Journal.
  6. ↑ Clinical trial number NCT07672405 for "Sorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TB" at ClinicalTrials.gov
  7. ↑ Clinical trial number NCT06058299 for "Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis" at ClinicalTrials.gov
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.